Advanced Science：暨南大学黄俊祺等揭示铁死亡抵抗新机制

Core Viewpoint - Ferroptosis is emerging as a significant regulatory pathway in various diseases, including tumors and acute kidney injury, with potential clinical applications [3][4]. Group 1: Research Findings - The study identifies the ERM (Ezrin-Radixin-Moesin) protein family as a regulatory switch for ferroptosis sensitivity, linking mechanical signals and oxidative stress through the "ERM-Actin-ROS-NRF2-HMOX1" signaling axis [4][6]. - Inhibition of ERM proteins using inhibitors NSC305787 and NSC668394 leads to a transient increase in ROS levels, activating NRF2 and upregulating antioxidant genes like HMOX1, thereby blocking lipid peroxidation and ferroptosis [6][7]. - The research demonstrates that low concentrations of various ROS inducers can inhibit ferroptosis via the NRF2-HMOX1 axis, suggesting that "controlled oxidation" may represent an under-evaluated strategy for ferroptosis inhibition [7]. Group 2: Implications for Future Research - The findings provide experimental evidence for targeting ERM protein functions, actin cytoskeleton remodeling, or fine-tuning ROS thresholds as interventions for ferroptosis [7]. - The study emphasizes the need for systematic evaluation of candidate compounds' ROS-inducing capabilities in future ferroptosis inhibitor research, considering the concentration-dependent effects [7].